Compare Mesoblast Limited (MESO) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs NEOS S&P 500 High Income ETF — how do they compare? Mesoblast Limited trades at $14.24 (market cap $1.75B), while NEOS S&P 500 High Income ETF trades at $54.09 (market cap $12.50B). The key difference: NEOS S&P 500 High Income ETF is far larger — about 7.1× Mesoblast Limited's market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and NEOS S&P 500 High Income ETF for 58 Days on average.
| MESO | SPYI | |
|---|---|---|
Market Cap | $1.75B | $12.50B |
Volume | 239,027 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $20.96 | $54.42 |
52-Week Low | $13.19 | $47.98 |
Typical Hold Time | 15 Days | 58 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
SPYI trades at $54.095 with a modest 0.16% daily gain, showing bullish technical momentum with strong moving average signals. The ETF maintains consistent monthly dividend distributions around $0.53-0.54 per share, targeting income-focused investors. Recent news highlights SPYI's popularity among retirement portfolios while raising concerns about principal erosion from covered call strategies.
The outlook remains mixed - strong technicals and high yield appeal support near-term stability, but long-term capital preservation risks from the covered call strategy warrant caution. Income investors benefit from consistent distributions, though growth-oriented investors may find the strategy limiting during bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
